The Role of Artificial Intelligence on Tumor Boards: Perspectives from Surgeons, Medical Oncologists and Radiation Oncologists.

Journal: Current oncology (Toronto, Ont.)
PMID:

Abstract

The integration of multidisciplinary tumor boards (MTBs) is fundamental in delivering state-of-the-art cancer treatment, facilitating collaborative diagnosis and management by a diverse team of specialists. Despite the clear benefits in personalized patient care and improved outcomes, the increasing burden on MTBs due to rising cancer incidence and financial constraints necessitates innovative solutions. The advent of artificial intelligence (AI) in the medical field offers a promising avenue to support clinical decision-making. This review explores the perspectives of clinicians dedicated to the care of cancer patients-surgeons, medical oncologists, and radiation oncologists-on the application of AI within MTBs. Additionally, it examines the role of AI across various clinical specialties involved in cancer diagnosis and treatment. By analyzing both the potential and the challenges, this study underscores how AI can enhance multidisciplinary discussions and optimize treatment plans. The findings highlight the transformative role that AI may play in refining oncology care and sustaining the efficacy of MTBs amidst growing clinical demands.

Authors

  • Valerio Nardone
    Department of Precision Medicine, University of Campania "L. Vanvitelli", Naples, Italy.
  • Federica Marmorino
    Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, 56126 Pisa, Italy.
  • Marco Maria Germani
    Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, 56126 Pisa, Italy.
  • Natalia Cichowska-Cwalińska
    Department of Oncology and Radiotherapy, Medical University of Gdańsk, 80-210 Gdańsk, Poland.
  • Vittorio Salvatore Menditti
    Department of Precision Medicine, University of Campania "L. Vanvitelli", 80131 Naples, Italy.
  • Paolo Gallo
    Department of Precision Medicine, University of Campania "L. Vanvitelli", 80131 Naples, Italy.
  • Vittorio Studiale
    Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, 56126 Pisa, Italy.
  • Ada Taravella
    Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, 56126 Pisa, Italy.
  • Matteo Landi
    Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, 56126 Pisa, Italy.
  • Alfonso Reginelli
    Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Napoli, Italy.
  • Salvatore Cappabianca
    Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138, Naples, Italy.
  • Sergii Girnyi
    Department of General Surgery and Surgical Oncology, "Saint Wojciech" Hospital, "Nicolaus Copernicus" Health Center, 80-462 Gdańsk, Poland.
  • Tomasz Cwalinski
    Department of General Surgery and Surgical Oncology, "Saint Wojciech" Hospital, "Nicolaus Copernicus" Health Center, 80-462 Gdańsk, Poland.
  • Virginia Boccardi
    Division of Gerontology and Geriatrics, Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy.
  • Aman Goyal
    Intern, Department of Medicine, Seth GS Medical College and King Edward Memorial (KEM) Hospital, Mumbai, Maharashtra, India.
  • Jaroslaw Skokowski
    Department of General Surgery and Surgical Oncology, "Saint Wojciech" Hospital, "Nicolaus Copernicus" Health Center, 80-462 Gdańsk, Poland.
  • Rodolfo J Oviedo
    Nacogdoches Medical Center, Nacogdoches, TX 75965, USA.
  • Adel Abou-Mrad
    Centre Hospitalier Universitaire d'Orléans, 45100 Orléans, France.
  • Luigi Marano